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Abstract
Background: Interleukin 11 (IL-11) is a pleiotropic cytokine with anti-apoptotic, anti-inflammatory and
hematopoietic potential. The IL-11 activity is determined by the expression of the IL-11R receptor alpha (IL-11Ra)
and the signal transducing subunit b (gp130) on the cell membrane. A recombinant soluble form of the IL-11Ra
(sIL-11Ra) in combination with IL-11 acts as an agonist on cells expressing the gp130 molecule. We constructed a
designer cytokine Hyper IL-11 (H11), which is exclusively composed of naturally existing components. It contains
the full length sIL-11Ra connected with the mature IL-11 protein using their natural sequences only. Such a
construct has two major advantages: (i) its components are as close as possible to the natural forms of both
proteins and (ii) it lacks an artificial linker what should avoid induction of antibody production.
Results: The H11 construct was generated, the protein was produced in a baculovirus expression system and was
then purified by using ion exchange chromatography. The H11 protein displayed activity in three independent
bioassays, (i) it induced acute phase proteins production in HepG2 cells expressing IL-11, IL-11Ra and gp130, (ii) it
stimulated the proliferation of B9 cells (cells expressing IL-11Ra and gp130) and (iii) proliferation of Baf/3-gp130
cells (cells not expressing IL-11 and IL-11Ra but gp130). Moreover, the preliminary data indicated that H11 was
functionally distinct from Hyper-IL-6, a molecule which utilizes the same homodimer of signal transducing receptor
(gp130).
Conclusions: The biologically active H11 may be potentially useful for treatment of thrombocytopenia, infertility,
multiple sclerosis, cardiovascular diseases or inflammatory disorders.
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Background
IL-11 is a pleiotropic cytokine, which exhibits multiple
biological activities which are determined by expression
of IL-11Ra and gp130 on the cell membrane [1]. Origin-
ally it was identified in 1990 as a molecule promoting
growth of the IL-6-dependent mouse plasmacytoma cell
line B9 [2]. It has been demonstrated later, that IL-11
exhibits multiple effects not only on hematopoietic
system, but it also acts on various cell types of the liver,
gastrointestinal tract, lung, heart, central nervous system,
bone, joint and immune system [1]. IL-11 acts synergisti-
cally with other growth factors in the process of
hematopotic cells differentiation including progenitor
cells, and on megakaryocytopoiesis, thrombopoiesis,
erythropoiesis and myelopoiesis [1]. Moreover, IL-11 dis-
plays anti-melanoma activity when used as molecular
adjuvant in the therapeutic whole cell melanoma vaccine
formulation [3].
IL-11 together with IL-6, IL-27, Leukemia Inhibitory
Factor (LIF), Oncostatin M (OSM), Ciliary Neurotrophic
Factor (CNTF), Cardiotrophin 1 (CT-1), cardiotrophin-
like cytokine (CLC) and neuropoietin (NP) belongs to the
family of hemopoietic cytokines (named IL-6-type or
gp130 cytokines), which share structural similarity and a
common receptor subunit (gp130) [4,5]. Some of the IL-6-
type cytokines require a specific (unique) receptor com-
plex, however, always one or two subunits of a common
transmembrane transducer receptor gp130 is required.
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type cytokines like LIF, CT-1, CNTF, NP, CLC need LIF
receptor (LIFR) and gp130. OSM binds first to gp130 and
then with either LIFR or OSMR. IL-27 forms signaling
complex with gp130 and WSX-1 (IL-27R). Moreover,
some of the IL-6 type interleukins first bind to a specific
receptor alpha and then engage signal transducer subunits
[6]. Cytokines utilizing gp130 molecule induce signaling
via the Janus Kinase/Signal Transducer and Activator of
Transcription (JAK/STAT) pathway and also the Mitogen-
Activated Protein Kinase (MAPK) cascade [7].
Specifically, the IL-11 receptor complex is formed via
three separate events. First, IL-11 binds with low affinity
to membrane specific receptor a. Next, IL-11/IL-11Ra
heterodimer binds with high affinity to receptor gp130
forming heterotrimer. At the last stage, the heterotrimers
associate forming a hexameric complex that elicits the bio-
logical response. The stoichiometry of the high affinity IL-
11 receptor complex has been determined in vitro as a
hexamer consisting of two IL-11 molecules, two IL-11Ra
chains and a homodimer of two gp130 molecules [8].
The gp130 protein was found on all human cell types so
far studied, however the expression of other IL-6-type
receptor subunits is limited. Cells that express the proper
subunit will be sensitive to the respective cytokine. More-
over, soluble forms of the alpha receptors lacking the
transmembrane and cytoplasmic domains were found [7].
Soluble forms of cytokine receptors can be produced by
limited proteolysis of the membrane-bound receptor or by
translation of alternatively spliced mRNA [9]. Cells that do
not express receptor a can be sensitive to the complex of
cytokine/soluble cytokine receptor a. Recombinant soluble
IL-11Ra (sIL-11Ra) can bind IL-11 and then the comples
attracts gp130 leading to signal transduction [10]. The
complex of IL-11/sIL-11Ra can activate cells bearing both
IL-11Ra and gp130 subunits or gp130 only. The recombi-
nant sIL-11Ra acts in vitro as IL-11 agonist, although
antagonizing activity was also observed [10-12].
In order to increase and modify the potential bioactiv-
ity of some cytokines, the idea of linking of two soluble,
naturally existing components was postulated. The
fusion proteins are expected to be more stable and are
needed at a lower effective dose. Examples derived from
IL-6-type cytokines include fusion proteins consisting of
different fragments of alpha receptors and their cognate
cytokines like IL-6/sIL-6R (Hyper IL-6), IL-11/sIL-11Ra
(IL-11/R-FP) and CNTF/sCNTFR (Hyper-CNTF)
[13-15]. Here, we constructed a novel cytokine Hyper
IL-11 (H11), which is composed of naturally existing
components only. It contains the full length soluble IL-
11Ra connected with IL-11. Since the natural sequence
of C-terminus of IL-11Ra and N-terminus of IL-11
were used, we could refrain from using artificial linker
sequences for the connection of both components.
Results
Construction of H11
Our new designer cytokine Hyper IL-11 (H11) is com-
posed exclusively of naturally existing components. It con-
tains the full length soluble IL-11Ra connected with IL-
11. The cDNA fragment of s IL-11Ra (position 1-1095)
and the cDNA of IL-11 (position 55-600) were amplified
by PCR. The forward primer contained an additional
recognition sequence for the restriction enzyme SalI.
Moreover, ACC nucleotides in front of ATG and substitu-
tion A for G just after the translational start codon ATG
were introduced in order to provide the Kozak consensus
sequence and a restriction site NcoI, respectively. The
reverse primer for amplification of IL-11Ra contained an
additional 5’ overlapping sequence on IL-11 at position 86
where a natural restriction site XhoI occurs. Moreover, the
amplified fragment omitted the leader sequence of IL-11
with exception of natural sequence coding the last three
amino acids (AVA) of the leader sequence which are now
at the N termini of the IL-11 component. The restriction
site XhoI was used to connect both components. The
membrane proximal region of the IL-11Ra (51 amino
acids) and the 16 N-terminal residues of IL-11 are not
helical and presumably flexible enabling the proper assem-
bly of the complex. The sequence and schematic represen-
tation of the fusion complex are shown in Figure 1.
Moreover, the details of the H11 construction have been
described in Patent No WO2005113591 [16].
Production and purification of H11 protein
The production of recombinant H11 protein was carried
out in a Baculovirus expression system. High-Five BTI-
TN-5B1-4 insect cells were used, which were transduced
at a density of 1x10
6 cells/ml using MOI 5. The H11
production was carried out for 48 h in Express Five
SFM medium. The purification of fusion protein was
carried out by ion exchange chromatography. Purified
H11 from the Q Sepharose XL bed was eluted at 50
mM NaCl/20 mM 1,3 diaminopropane buffer pH 10.5.
The quality and quantity of the fusion protein was
determinated by SDS-PAGE gel electrophoresis and
Western blot analysis (Figure 2). The intensive band,
which migrated in SDS-PAGE below 66 kDa BSA (data
not shown), was recognized by anti- IL-11Ra antibody
which binds H11. The observed molecular weight of
H11 was slightly above the calculated one (58.8 kDa)
what might be due to the N-glycosylation. The N-glyco-
sylation of IL-11Ra was described before [13]. Although,
H11 produced in insect cells may differ in pattern of
glycosylation when compared with one produced in
mammalian cells [17]. the glycosylation was shown not
to be critical for ligand gp130 interaction [18]. The aver-
age yield of purified H11 was 646 μgf r o m1Lo fc e l l
supernatant.
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The purified recombinant H11 was tested for biological
activity in three different in vitro bio-assays: human
hepatoma cell line HepG2-assay, murine B9 (hybridoma
cell line) bio-assay, and murine Ba/F3-gp130 bio-assay.
Stimulation of a1 antitrypsin in HepG2 cells by H11.
HepG2 cells secrete endogenous IL-11, which makes them
unresponsive to exogenous IL-11. However, HepG2 insen-
sibility to IL-11 can be restored by the addition of s IL-
11Ra [10]. Incubation of HepG2 cells with H11 stimulated
in a dose dependent manner the expression and secretion
of a read-out plasma protein-a1 antitrypsin as measured
by rocket immunoelectrophoresis (Figure 3).
Proliferation of B9 cells. B9 cells express IL-11Ra and
gp130 receptors, making them responsive to IL-11 [19].
Stimulation of B9 cells with IL-11 and H11 led to induc-
tion of their proliferation (Figure 4). To obtain comparable
levels of B9 proliferation, H11 was applied at a 10-fold
lower molar concentration than IL-11. The highest prolif-
eration of B9 cells was achieved with 32000 pM IL-11.
Since no saturation was reached at this concentration, we
are not sure whether application of higher IL-11 concen-
tration would increase B9 proliferation further. Applica-
tion of IL-11 at higher dose was impossible due to the
technical reasons. When B9 cells were stimulated with
H11, a concentration of 6.25 pM was sufficient for maxi-
mal proliferation. The difference between IL-11 and H11
activity was probably due to the low expression of the IL-
11 receptor. Indeed, H11 composed of active IL-11 and
sIL-11Ra induced much stronger proliferation of B9 cells.
Proliferation of Ba/F3-gp130 cells. The unique feature
of Ba/F3 cells (pro-B lymphocyte cell line) is the lack of
membrane gp130 molecules, which makes them unre-
sponsive to IL-6 type cytokines. However, stable trans-
fection of Ba/F3 cells with gp130 cDNA made them
responsive to the combination of IL-6 type cytokine and
its a receptor [13,14]. Stimulation of Ba/F3-gp130 cells
with recombinant H11 led to their propagation, as mea-
sured using MTT test (Figure 5). Ba/F3-gp130 cells did
not proliferate in medium without stimuli however, H11
stimulated these cells in a at dose dependent manner.
T h eB a / F 3 - g p 1 3 0a s s a yp r o v e dt h a tt h en e wd e s i g n e r
cytokine H11 was acting as a complex.
Signal transduction mediated by H11
Signal transduction of IL-11 and related cytokines via
the common signal transducer gp130 is mediated by the
activation Jak/STAT and Ras/MAPK signaling pathways
Figure 2 Purification of H11-SDS-PAGE (A) and Western Blot (B)
analysis. The proteins were visualized with Roti-Blue stain and for
detection H11 the anti- IL-11Ra antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) was used. Lane 1- molecular weight marker
PageRuler (Fermentas), lane 2-supernatant from infected High-Five
BTI-TN-5B1-4 cells, 3-supernatant diluted with 20 mM 1.3 DAP (1:8),
4-eluted H11.
Figure 1 (A) Amino acid (AA) sequence of the fusion protein H11 and (B) Schematic representation of tertiary structure of the fusion
complex. (A) The N-terminal signal peptide is indicated by thick underline. The sequences of C-terminus of IL-11Ra and N-terminus of IL-11,
which form natural linker are boldface. The arrow indicates the fusion site. (B) The Ig-like region (D1 domain) and cytokine binding domains (D2
and D3) of IL-11Ra are indicated. The three receptor binding sites of IL-11 are shown. IL-11 binds the IL-11Ra though site I, while site II and III
are occupied by two gp130 molecules.
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dues of the receptors and subsequent recruitment of
STAT3/1 and SHP-2. In order to show that STAT3 acti-
vation was effected by H11, Ba/F3-gp130 cells were
stimulated with the hypercytokine and the phosphory-
lated forms of STAT3 (pSTAT3) were detected using
flow cytometry. As indicated in Figure 6, contrary to IL-
11, the stimulation with H11 led to activation of STAT
Figure 3 Rocket immunoelectrophoresis of supernatants from HepG2 cells. HepG2 cells were stimulated with recombinant H11 at various
concentrations. After 48 h the collected medium was analyzed by rocket immunoelectrophoresis for presence of a1-antitrypsin.
Figure 4 The proliferation assay of B9 cells. B9 cells (1 × 10
4 cells per well) were tested for proliferation at various concentrations of (A) IL-11
and (B) H11. The medium without stimulator was used as the negative control. The proliferation of the cells was measured after 3 days using
colorimetric assay based on MTT reagent.
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an altered mechanism.
Differentiation study of hematopoietic Lin-CD34+ cells
To order to compare the effects of Hyper-IL-6 and H11
on differentiation of Lin-CD34+ in liquid cell cultures,
analysis of expression of cell surface antigens was per-
formed on day 14 (Figure 7). Anti-CD15 antibody was
used to evaluate granulopoesis and anti-CD235a anti-
body to assess erythropoiesis. The number of cells
expressing myeloid marker CD15 was highest in cultures
containing Hyper-IL-6; (41% in Hyper-IL-6 vs. 35% in
control culture and 29% in H11-Figure 7A). In contrary,
H11 promoted differentiation of Lin-CD34+ towards
erythroid cells. The number of CD235a+ cells was 39%
in H11 stimulated culture, 27% in Hyper-IL-6 and 20%
in control culture (Figure 7B).
Discussion
Concept of the construction of recombinant fusion pro-
teins derived from IL-6 cytokines is not new. It is based
on the strategy of linking the cytokines and their cog-
nate soluble a receptor. The a receptors posses extra-
cellular N-terminal domain and one transmembrane
domain (with exception of CNTFR, which is linked to
the membrane by a lipid anchor). Structurally, following
predicted regions can be distinguished: (i) signal peptide,
(ii) Ig-like region-D1 domain, (iii) cytokine binding
homology domain (CHD) consisting of two fibronectin-
type-III-like domains (FNIII) termed D2 and D3., (iv)
receptor pre-membrane region, (v) transmembrane, and
(vi) cytoplasmic regions. The designed fusion proteins
contained different structural parts of its a receptor.
Hyper-IL-6 consisted of D2 and D3 domain of IL-6R a
chain (AA residues 113-323) connected to IL-6 (AA 29-
212) via artificial polypeptide linker [14]. Hyper-IL-6 is a
fully active fusion protein, which mediates response at
10-1000-fold lower doses as compared to the combina-
tion of soluble IL-6 and sIL-6R molecules [14]. In ana-
logy, another superagonist was designed named IL-11/
R-FP [13]. IL-11/R-FP was created by covalently linking
D2 and D3 domains of IL-11Ra (position L/109-G/318)
with IL-11 (position P/29-L/199) using a 21 amino acid
linker. It demonstrated 50 fold higher activity in vitro
than the combination of IL-11 and sIL-11Ra. However,
such construct was also composed of interleukin and a
truncated segment of the alpha receptor (as Hyper IL-
6), so it lacked naturally existing parts of the used
receptor. Moreover, the used artificial linker is not a
naturally occurring sequence, thus it might demonstrate
potential immunogenicity when used for treatment of
human patient. Hyper-CNTF was another example of a
superagonist composed of sCNTFR (AA 1-346) and
Figure 5 The proliferation assay of Ba/F3-gp130 cells.B a / F 3 -
gp130 (2 × 10
4 cells per well) cells were induced by H11 at various
concentrations. The medium without stimulator was used as the
negative control. The proliferation of the cells was measured after 3
days using colorimetric assay based on MTT reagent.
Figure 6 Phosphorylation of transcription factor STAT 3 analyzed by flow cytometry. Ba/F3 and Ba/F3-gp130 cells were stimulated with
control medium (unstimulated), hIL-11 or H11 and phosphorylation of STAT3 was measured using anti- STAT3P antibody.
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6 type fusion proteins (Hyper IL-6 and IL-11/R-FP),
since it included the Ig domain of sCNTFR. Although
the D3 domain of the interleukin alpha receptor is
mainly involved in ligand binding [20] and its D2-D3
part is sufficient to induce biological activity in vitro
[13,14], the role of the Ig-like domain and the mem-
brane proximal region can not be disregarded. It was
shown that the Ig-domain of the IL-6R is important for
intracellular transport of IL-6R through the secretory
pathway [21]. It can also be involved in interdomain sta-
bilization or induction of conformational change of the
ligand. Moreover, for fusion of CNTFR and CNTF the
C-terminal end of CNTFR and N-terminal end of CNTF
was used, which were linked by one additional glycine
residue [15]. A synthetic polypeptide linker was not
applied in order to minimize potential immunogenicity.
The mentioned terminal ends are presumably flexible
and sufficient to allow access of cytokine to its receptor
alpha binding sites. Indeed, Hyper-CNTF was biologi-
cally active [15]. In terms of construction, our Hyper-IL-
11 (H11) resembles mostly Hyper-CNTF. It is composed
of full length of soluble IL-11 receptor and IL-11, and
both elements are connected by natural existing parts of
receptor and interleukin. It differs from Hyper-CNTF,
since the additional glycine residue was not incorporated
in the fusion and also the flexible termini of sIL-11Ra
and IL-11 generated a longer linker. For construction of
Hyper-IL-6, a 29 AA linker was used, while for IL-11/R-
FP 31 AA and Hyper-CNTF 31 AA were applied
[13-15]. With our hyper-molecule, a 67 AA linker was
generated, since the pre-membrane region of IL-11Ra
(51 amino acids) together with 16 N-terminal residues
of IL-11 is not helical and presumably flexible. It should
enable the proper positioning of the fusion molecule. In
general, the construction of our hyper-cytokine has two
major advantages: (i) its components are as close as pos-
sible to the natural forms of both proteins and (ii) omit-
ting of the artificial linker should prevent possible
immunogenicity and other side effects due to the non-
natural recombinant agent.
In the case of Hyper-IL-6, the high potency of the
designer cytokine is based on the fact that the affinity of
IL-6 to the IL-6R is in the range of 1 nM whereas the affi-
nity of the complex of IL-6 and IL-6R is 6R is around 10-
15 pM, which is about 100 times higher. If the affinities
between IL-11 and the two receptor subunits are in the
same range, this would explain the high biologic activity of
the H11 protein.
Although sIL-11Ra was not found in human body fluids
so far, its existence has been postulated due to identifica-
tion of a transcript potentially encoding sIL-11Ra [22].
The recombinant sIL-11Ra in vitro acts as IL-11 agonist
[10-12]. In addition, the sIL-11Ra not only potentiated
effects of the IL-11 on cells that are normally responsive
to IL-11, but also in the presence of IL-11 it mediated a
signal transduction in cells expressing gp130 molecules
only [10,12]. However, the concentration of IL-11 required
to mediate a biological response using sIL-11Ra had to be
10- 20-fold higher than using membrane receptor [11].
Expression of IL-11Ra is limited to certain cell types,
while gp130 is present on all cells of the body. Thus, the
use of the sIL-11Ra significantly widens the range of IL-11
bioactivity. Furthermore, sIL-11Ra can act as an IL-11
antagonist when tested on cells expressing the membrane
IL-11Ra and gp130 [11]. The antagonism probably
resulted from the competition between soluble and cellu-
lar IL-11Ra for IL-11 and/or was depended on the num-
ber of gp130 molecules [11]. Our Hyper-IL-11 acts as
agonist when tested in HepG2-assay, in B9 and in Ba/
F3gp130 bio-assays. Since sIL-11Ra presumably is already
occupied by IL-11, it does not compete with endogenous
Figure 7 Effect of Hyper-IL-6 and H11 on the differentiation of cord blood-derived lineage-depleted CD34+ hematopoietic progenitor
cells. Cells were seeded in X-Vivo 10 medium supplemented with rhSCF and rhIL-6 (control) and in the presence of Hyper-IL-6 or H11. After day
14 cells were harvested and analyzed by flow cytometry for the expression of CD15 (A), and CD235a (B).
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agonistic activity. The previously described molecule IL-
11/R-FP also acted as agonist when tested in HepG2 and
Ba/F3-gp130 assays [13]. When Ba/F3-gp130 cells were
stimulated with IL-11/R-FP, a concentration 130-140 pM
was sufficient for half-maximum proliferation. Our H11
induced the half-maximum proliferation at the dose of
approximately 800-900 pM. However, IL-11/R-FP was
non purified and its calculated concentration could be
misleading. According to Pflanz et al. the concentration of
IL-11/R-FP in the yeast supernatant was calculated from
the band intensities of IL-11/R-FP and serial dilutions of
IL-11 preparation of a known concentration measured by
a Lumi-Imager [13]. Since the analyzed material was
derived from not purified yeast supernatant, presumably
the concentration was calculated after immunoblotting (it
was not defined). Our experience indicated that antibodies
anti IL-11 or IL-11Ra not necessarily recognize fusion
molecule with the same affinity. When several ELISA sys-
tems were used to measure H11 concentration, different
results were obtained (data not shown). The antigenic
determinant at a fusion molecule may be hidden or par-
tially hidden when compared with the epitope of parental
components (IL-11 or IL-11Ra), what can explain the
observed differences. In order to compare correctly the
activity of both fusion proteins (H11 and IL-11/R-FP) the
experiment should be conducted simultaneously using
purified proteins, which concentration was calculated with
the same method.
After binding to their cognate a receptor, cytokines IL-
6 and IL-11 engage a homodimer of gp130 in order to
elicit signal transduction. Since, both designer cytokines,
H11 and Hyper-IL-6 compromise of cytokine and its cog-
nate a receptor, they need the same receptor subunits for
signal transduction. That is why H11 and Hyper-IL-6
may be functionally equivalent. According to our preli-
minary results H11 retains in part an IL-11Ra-specific
activity that is directed by H11 interaction with gp130. In
terms of hematopietic differentiation H11 increased
expression of early erythroid antigen. IL-11 is well known
to be involved in the expansion of megakaryiocyte pro-
genitors, and megakariocytes derive from common mega-
karyocyte/erythrocyte progenitor [23]. However, Hyper
IL-6 did not exert the same effect. Contrary, it stimulated
myelopoiesis, what is in agreement with previous data
[14]. Although, IL-6 and IL-11 share the common recep-
tor subunit (gp130), they bind to the different sites on it
[24,25], what can influence on the specific response
mediated by gp130 signaling. The proliferation of TF1
cells induced by IL-11 but not by IL-6 could be inhibited
by a specific antibody anti gp130 (B-P4). On the other
hand, using SK-N-MC cells, the same antibody could not
block the phosphorylation of gp130 induced by IL-11
and by IL-6 [24]. Moreover, PHA-activated T-cells
responded to IL-6 by mobilization of a heterodimer
STAT1/STAT3 and homodimer STAT1, while IL-11/
sIL-11Ra by a STAT3 homodimer and STAT3/STAT1
heterodimer [10]. These results indicated that although
structurally cytokines share the same signal transducing
unit, its activation may elicit different effects, like differ-
ent global phosphorylation level, activation of different
STAT molecules what may influence the final biological
activity. Such difference may be critical to activation of
distinct regulation processes depending on the cell origin.
However, whether this kind of differences are responsible
for diverse action of H11 and Hyper-IL-6 needs to be
evaluated.
Since IL-11 is a pleiotropic cytokine of hematopoietic
and anti-inflammatory properties, H11 may be poten-
tially beneficial in the treatment of various diseases. IL-
11 is the only agent approved by USA Food and Drug
Administration (FDA) to prevent severe thrombocytope-
nia and reduce the need for platelet transfusion follow-
ing myelosuppressive chemotherapy for non-myeloid
malignancies. Accordingly, studies of H11 in similar
models are required. Even if in vivo studies demonstrate
unacceptable toxicity it does not exclude utility of H11
for ex vivo expansion of megakaryocyte precursor cells.
Our preliminary in vitro studies have indicated great
potential of H11 for megakaryocyte expansion (data not
shown). Moreover, recent studies have shown that IL-11
regulated the autoimmune demyelination disease-multi-
ple sclerosis (MS) [26]. Due to its dual action: immuno-
modulatory and neuroprotective/regenerative, IL-11 may
display a unique potential to treat MS. Loss of IL-11Ra
expression was associated with severe symptoms of
autoimmune encephalomyelitis (EAE) in the mouse
model of MS. IL-11 treatment of mice with EAE gave
partial, albeit statistically significant, therapeutic benefit.
Another example of potential H11 utility is to treat
infertility. Mice lacking IL-11Ra are infertile due to
defective uterine response to implantation [27]. Accord-
ingly, H11 which can omit IL-11Ra and directly achieve
gp130 may prove to be beneficial in pregnancy.
Conclusions
We constructed a designer cytokine Hyper IL-11 (H11),
which is exclusively composed of naturally existing com-
ponents. It contains the full length sIL-11Ra linked with
the IL-11 using their natural sequences. Accordingly,
H11 should not induce of the antibody production and
other side effects due to the non-natural recombinant
agent. The purified recombinant H11 is a fully active
protein. It displayed biological activity in three different
in vitro bio-assays: human hepatoma cell line HepG2-
assay, B9 and Ba/F3-gp130 proliferation assays. More-
over, it differs in terms of differentiation of hematopoie-
tic cells when compared to the Hyper-IL-6.
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IL-11Ra, H11 may be potentially applied in the biome-
dical field. It may be useful for treatment of thrombocy-
topenia, infertility, multiple sclerosis, cardiovascular
diseases or inflammatory disorders. It should be noted
however, that due to the fact that Hyper-IL-11 could sti-
mulate all cells in the body, a strategy to properly target
the designer cytokine needs to be developed.
Methods
Cell culture
Insect cell culture. Sf21 (Spodoptera frugiperda)a n d
High-Five BTI-TN-5B1-4 (Trichoplusia ni) insect cells
were routinely cultured at 28°C in ambient CO2 in
Grace’s Insect Cell Culture Medium supplemented with
10% Fetal Calf Serum (FCS) and Express Five SFM med-
ium, respectively. Monolayer cultures of Sf21 were
adapted to suspension growth in Sf-900 II SFM medium
on an orbital shaker platform rotating at 150 rpm. For
adaptation of High-Five BTI-TN-5B1-4 cells to suspen-
sion culture, aggregated cell clamps were allowed to set-
tle for 2 min and then samples for subculturing were
taken from the upper layer of the culture. Cells were
cultured in 500 ml shake flasks on an orbital shaker
platform rotating at 150 rpm. All cell culture media and
FCS were of Gibco Invitrogen Corporation (Grand
Island, NJ) brand.
Mammalian cell culture. Human hepatoma cells
(HepG2) were maintained in DMEM (Gibco Invitrogen,
Grand Island, NJ) medium supplemented with 10% FCS.
The B9 cell line, a variant of the IL-6 dependent murine
hybridoma B13.29, was routinely cultured in DMEM
containing 10% FCS and 10% conditioned medium from
B 7 8 - I L - 6c e l ll i n e( as o u r c eo fI L - 6 ) ’ [28]. The murine
bone marrow-derived pro-B-cell line Ba/F3 stably trans-
fected with a gp130 cDNA (Ba/F3-gp130) was main-
tained in DMEM medium supplemented with 10% FCS
and 0.5 ng/ml mIL-3 (Sigma, St. Louis, MO). Lin-CD34
+ cells were cultured in serum free X-Vivo10 culture
medium (Lonza, Verviers, Belgium). All media contained
80 mg/l gentamycin (KRKA, Novo Mesto, Slowenia) and
c e l lc u l t u r e sw e r eg r o w na t3 7 ° Ci na na t m o s p h e r eo f
95% air-5% CO2.
Construction of hyper IL-11 (H11)
The fragment of human IL-11 cDNA (sequence which
corresponds to the amino acid residues 19-199, Gen-
Bank:ID: X58377) was amplified by a standard PCR
reaction. The amplified fragment of IL-11 was cloned
into the pGEM-Teasy vector (Promega, Madison, WI).
The cDNA of human IL-11Ra (the amino acid residues
1-365, GenBank:ID: Z388102) was also amplified by
PCR. Sequences of the used primers were as follows: IL-
11 forward: 5’ GCT GCT GCC CCT GGG CCA, IL-11
reverse: 5’ T C CG C GG C CG C TA T GG C CG A CG T C
GAC TCA CAG CCG AGT CTT CAG, IL-11Ra for-
ward: 5’ ACG CGT CGA CGC CAC CAT GGG CAG
CAG CTG CTC AGG GCT G, IL-11Ra reverse: 5’ AAC
TCG AGG GGG GCC AGG TGG TGG CCC AGG
GGC GAC AGC CTG CTC CAC AGA GTC CCT. The
IL-11Ra PCR product was cloned into the pGEM-Teasy
vector and then digested with SalIa n dXhoIr e s t r i c t i o n
enzymes. The purified fragment SalI/XhoI was cloned
into XhoI site of the plasmid pGEM-Teasy/IL-11 leading
to the creation of the fused cDNA of IL-11Ra and IL-11
referred as Hyper IL-11 (H11). The sequence has been
confirmed by DNA sequencing.
Restriction, DNA modification and amplification
enzymes were supplied by Promega (Madison, WI). PCR
and plasmid DNA fragments were purified using a QIA-
quick gel extraction kit (Qiagen, Hilden, Germany) as
recommended by the manufacturer. Plasmid DNA was
isolated using a QIAprep Spin miniprep Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
protocol.
Production of recombinant H11
For production of recombinant H11 the Bac-To-Bac
Baculovirus Expression System was used (Invitrogen Cor-
poration, Carlsbad, CA). First, the pGEM-Teasy/H11
plasmid was digested with SalI/SphI restriction enzymes
and the purified cDNA coding for H11 was cloned into
the SalI/SphI of pFastBac1 plasmid. The pFastBac1/H11
plasmid was transformed into DH10Bac competent cells,
which contain the bacmid with a mini-attTn7 target site
and the helper plasmid. The mini-Tn7 element on the
pFastBac1 donor plasmid was transposed to the mini-
attTn7 target site on the bacmid in the presence of trans-
position proteins provided by the helper plasmid. The
transformed cells were plated on LB-agar plates contain-
ing 50 μg/ml kanamycin, 7 μg/ml gentamycin, 10 μg/ml
tetracycline, 300 μg/ml Bluo-gal, and 40 μg/ml IPTG.
The selected, white colonies were grown in 3 ml clutures
overnight and plasmid DNA was isolated. The obtained
DNA was analyzed by PCR reaction to confirm the pre-
sence of the inserted gene. The following primers were
used: Forward #9: 5’ ACC CAC CCG CTA CCT CAC
CT, Reverse #2: 5’ GTC AGG AGC ACG GTG CT.
Propagation the recombinant baculovirus.T h eS f 2 1
cells were transfected with recombinant bacmid DNA
using Effectene Transfection Reagent (Qiagen, Hilden,
Germany) according to the manufacturer’s instruction.
Shortly, 8 × 10
5 cells were seeded into Grace’s Insect Cell
Culture Medium supplemented with 10% FCS in 35 mm
well of a 6-well plate and incubated overnight. For trans-
fection-complex formation, 1 μgo fb a c m i dD N Aw a s
mixed with 8 μl of Enhancer and 25 μl of Effectene
Transfection Reagent. After 10 min incubation, the
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10% FCS was added and transferred onto the cells. After
3 days, supernatant was collected and the titer of the
virus was assessed using the end-point dilution method
according to established procedures [29]. For amplifying
viral stocks, 1.4 × 10
6 of Sf21 cells suspended in Sf-900 II
SFM (Gibco Invitrogen, Grand Island, NJ) medium were
infected at Multipicity of Infection (MOI) 0.1 for 72 h.
The amplifying procedure of the recombinant H11 bacu-
lovirus was performed twice and finally the high-quality,
high- titer (2.87 × 10
8 pfu/ml) master virus stock was
obtained. The recombinant virus stock was stored at
-80°C.
Optimizing of heterologus protein production.I no r d e r
to achieve an optimal production of recombinant H11
protein, different factors, such as cell lines (Sf21 and
High-Five BTI-TN-5B1-4), medium (Sf-900 II SFM and
Express Five SFM), parameters of viral infection (MOI)
and expression kinetics were considered. To express the
recombinant gene product, suspension cultures at a cell
d e n s i t yo f1 ,1 . 5 ,a n d2×1 0
6 cells/ml were infected at
M O I0 . 5 ,1 ,5 ,a n d1 0p f u / m la n de x p r e s s i o no fH 1 1
was monitored by dot blot analysis at different harvest
times. Optimal production of recombinant H11 protein
was achieved at cell density of 1 × 10
6 cells/ml at MOI
5 for 48 h using High-Five BTI-TN-5B1-4 cells in
Express Five SFM medium. Moreover, production of
H11 was performed in the presence of Protease Inhibi-
tor Cocktail for use in culture medium (Sigma, St.
Louis, MO) at 1:1000 dilution. For dot-blot analysis,
hIL-11Ra polyclonal antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) and goat anti rabbit IgG-HRP
antibody (DakoCytomation, Glostrup, Denmark) and
ECL- kit (Amersham Bioscences, Uppsala, Sweden) were
used.
Purification and gel analysis of recombinant H11 protein
Harvested supernatant was diluted with 20 mM 1,3 dia-
minopropane buffer pH 11.8 at the ratio of 1: 8. Next, the
precipitated components were removed by centrifugation
at 8 000 g/4°C and batch IEX chromatography was per-
formed overnight at 4°C using Q Sepharose XL anion
exchange bed (Amersham Bioscences, Uppsala, Sweden).
The Q Sepharose XL was transferred to column and
absorbed proteins were eluted using a gradually increas-
ing gradient of salt (0-1 M NaCl) in 20 mM 1,3 diamino-
propane buffer pH 10.5. Collected fractions were
analyzed by SDS-PAGE gel electrophoresis and Western
Blot. Proteins were separated in 10% SDS-PAGE gel and
stained with Roti-Blue, Colloidal Coomassie staining
(Carl Roth, Karlsruhe, Germany) according to the manu-
facturer’s protocol. For Western blot analysis, the sepa-
rated proteins were transferred to a PVDF membrane by
a semi-dry electroblotting and then blocked in a solution
of 10% BSA (Sigma, St. Louis, MO) in TBS-N buffer. For
detection of H11, the antibodies and chemiluminescence
reagent were used as mentioned before for dot blot ana-
lysis. Selected fractions containing recombinant H11 pro-
tein were pooled and concentrated by membrane
filtration using membranes with a cut-off of 30 kDa
( M i l l i p o r e ,J a f f r e y ,N H ) .P D - 1 0D e s a l t i n gC o l u m n s
(Amersham Biosciences, Uppsala, Sweden) were used for
buffer exchange to PBS and H11 was sterilized by filtra-
tion using an Ultrafree-MC sterile 0,22 μm filter unit
(Millipore, Jaffrey, NH). The concentration of H11 was
estimated by analyzing the band intensities of H11 and
serial dilution of BSA of a known concentration using
Kodak Molecular Imaging Software v4.5.1.
Stimulation of a1 antitrypsin in HepG2 cells by H11
5×1 0
5 of HepG2 cells were seeded on a 48 well plate and
incubated overnight. Next day, cells were washed with
serum-free DMEM and then induced with H11 in serum-
free medium containing 1 μM dexamethasone. After 48 h
supernatants were collected and the amounts of a1 anti-
trypsin were measured by rocket immunoelectrophoresis
using antibody containing 1% agarose gels [30]. The anti-
body used for this study (Anti-a1-Antitrypsin IgG) was
from Sigma (St. Louis, MO). The experiment was repeated
three times in duplicate.
Proliferation assays
The B9 cells (1 × 10
4 cells/well) were seeded on 96 well
plate. Next, the cells were induced with recombinant
hIL-11 (Sigma, St. Louis, MO) or H11 at concentrations
indicated in Figure 4. The medium without stimulator
was used as a negative control. The proliferation of the
cells was measured after 72 h using a colorimetric assay
based on the MTT reagent (Sigma, St. Louis, MO). For
Ba/F3-gp130 studies, 2 × 10
4 cells per well were seeded
on 96 well plates in complete medium and stimulated
with increasing concentrations of H11. After 72 h of
incubation, proliferation of Ba/F3-gp130 cells was quanti-
fied using the MTT reagent. The absorbance of the sam-
ples was measured at 562 nm with a microplate reader
ELX808IV (Bio-Tek Instruments, Winooski, VT). Each
experiment was carried out three times in triplicate.
STAT3 activation in response to hIL-11 and H11
Ba/F3 and Ba/F3-gp130 cells were incubated for 2 h in
serum-free medium. Next, 1 × 10
6 cells were stimulated
with hIL-11, H11 or control medium. After 15 min incu-
bation at 37°C, cells were fixed with Fix Buffer I (BD Bios-
ciences Pharmingen, San Jose, CA), washed twice with
staining buffer (PBS-0.1%BSA-0.1%NaN3) and permeabi-
lized by adding Perm Buffer III (BD Biosciences Pharmin-
gen, San Jose, CA) and incubating for 30 min on ice. After
washing, intracellular staining was performed by adding
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Biosciences Pharmingen, San Jose, CA) or Alexa Fluor
647-IgG2a isotype control (BD Biosciences Pharmingen,
San Jose, CA). Cells were incubated in the dark for 30 min
at room temperature, washed and suspended in 0.5 ml
PBS. Analysis of the cells was performed by using a BD
Biosciences FACSCANTO flow cytometer and FACS-
DIVA software. The experiment was repeated three times.
Propagation and differentiation of human Lin-CD34+ cells
Isolation and culture of human Lin-CD34+ cells. Human
Lin-CD34+ cells were isolated from fresh cord blood.
Light density cells were separated by Ficoll-Hypaque den-
sity centrifugation (Sigma, St. Louis, MO). Mature hema-
topoietic cells such as T cells, B cells, NK cells, dendritic
cells, monocytes, granulocytes and erythroid cells were
removed by using the Lineage Cell Depletion Kit human
(Miltenyi Biotec Inc., Auburn, CA). Resulting Lin-cell frac-
tion was enriched for CD34+ cells by using the CD34
MicroBead Kit human (Miltenyi Biotec Inc., Auburn, CA).
Lin-CD34+ cells were cultured in 48-well plates (5 × 10
4
cells per well) in X-Vivo10 culture medium supplemented
with cytokines: cocktail 50 ng/ml rhSCF (PreproTech Inc.
Rocky Hill, NJ) and 20 ng/ml rhIL-6 (PreproTech Inc.
Rocky Hill, NJ) as control plus 50 ng/ml Hyper-IL6 or
50 ng/ml H11. Hyper-IL-6 was constructed and produced
as described previously [14,31]. Viability and cell number
was counted twice weekly. Cells were cultured for two
weeks.
Flow cytometric analysis. The differentiation of Lin-
CD34+ was evaluated by flow cytometry. Cells were
washed twice with PBS and stained for 30 min at 4°C
with combinations of the following murine monoclonal
antibodies: phycoerythrin (PE)-labeled anti-CD15 (Coul-
ter Beckman, Marseille, France) and phycoerythrin-Cy7
(PE-Cy7)-labelled anti-CD235a (Beckman Coulter,
Marseille, France). After labeling procedures, cells were
washed once with PBS and analyzed using Coulter Beck-
man Navios flow cytometer and FlowJo software.
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